For the week ending June 1, 2012, Roche is down 2% for the week and down 4% for the year. Over the same timeframe, Chromadex is up 27% for the past week and 27% for the year. I know Roche has some decent products, but I think the market is figuring out that Chromadex has better products, and that Chromadex is likely to take some obesity/weight loss business from Roche is the coming year. My bet is that Chromadex’s business will pick up further steam after it announces its study results in the next few weeks. The place to be is Chromadex, not Roche.